Poseida Therapeutics Inc
NASDAQ:PSTX

Watchlist Manager
Poseida Therapeutics Inc Logo
Poseida Therapeutics Inc
NASDAQ:PSTX
Watchlist
Price: 9.5 USD -0.63% Market Closed
Market Cap: $926m

Net Margin

-40.3%
Current
Improving
by 66.5%
vs 3-y average of -106.8%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-40.3%
=
Net Income
$-60.8m
/
Revenue
$150.9m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-40.3%
=
Net Income
$-60.8m
/
Revenue
$150.9m

Peer Comparison

Country Company Market Cap Net
Margin
US
Poseida Therapeutics Inc
NASDAQ:PSTX
925.4m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
395.2B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.2B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
175.6B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.9B USD
Loading...
AU
CSL Ltd
ASX:CSL
87.8B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.3B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 80% of companies in the United States of America
Percentile
20th
Based on 15 072 companies
20th percentile
-40.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Poseida Therapeutics Inc
Glance View

Market Cap
926m USD
Industry
Biotechnology

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of non-viral gene engineering technologies for the treatment of hematological malignancies and solid tumors. The company is headquartered in San Diego, California and currently employs 263 full-time employees. The company went IPO on 2020-07-10. The firm is focused on utilizing its genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure. The company is developing a portfolio of product candidates in a variety of indications based on its core platforms, including its non-viral piggyBac DNA Delivery System, Cas-CLOVER site-specific gene editing system and nanoparticle- and AAV-based gene delivery technologies. The firm's product candidate portfolio includes P-BCMA-101, P-PSMA-101, P-BCMA-ALLO1, P-MUC1C-ALL01, Dual CAR, P-OTC-101 and P-MMUT-101. Its lead product candidate, P-BCMA-101, is an autologous CAR-T targeting B cell maturation antigen (BCMA). P-PSMA-101 is an autologous CAR-T product candidate targeting prostate-specific membrane antigen (PSMA), being developed to treat patients with metastatic castrate resistant prostate cancer (mCRPC).

PSTX Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-40.3%
=
Net Income
$-60.8m
/
Revenue
$150.9m
What is Poseida Therapeutics Inc's current Net Margin?

The current Net Margin for Poseida Therapeutics Inc is -40.3%, which is above its 3-year median of -106.8%.

How has Net Margin changed over time?

Over the last 3 years, Poseida Therapeutics Inc’s Net Margin has increased from -400.6% to -40.3%. During this period, it reached a low of -443.9% on Mar 31, 2022 and a high of -18.6% on Jun 30, 2023.

Back to Top